Improved survival prediction for oropharyngeal cancer beyond TNMv8
AuthorsPrice, J M
West, Catharine M L
Homer, J. J.
Lee, Lip W
McPartlin, Andrew J
Sykes, Andrew J
Thomson, David J
AffiliationDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, The Christie NHS Foundation Trust, Manchester
MetadataShow full item record
AbstractPurpose: For oropharynx squamous cell carcinoma (OPSCC) this study aimed to: (i) compare 5-year overall survival (OS) stratification by AJCC/UICC TNM versions 7 (TNMv7) and 8 (TNMv8), (ii) determine whether changes to T and N stage groupings improve prognostication and (iii) develop and validate a model incorporating additional clinical characteristics to improve 5-year OS prediction. Material and methods: All OPSCC treated with curative-intent at our institution between 2011 and 2017 were included. The primary endpoint was 5-year OS. Survival curves were produced for TNMv7 and TNMv8. A three-way interaction between T, N stage and p16 status was evaluated for improved prognostication. Cox proportional hazards modelling was used to derive a new predictive model. Results: Of 750 OPSCC cases, 574 (77%) were p16-positive. TNMv8 was more prognostic than TNMv7 (concordance probability estimate [CPE] ± SE = 0.72 ± 0.02 vs 0.53 ± 0.02). For p16-positive disease, TNMv8 discriminated stages II vs I (HR 2.32, 95% CI 1.47-3.67) and III vs II (HR 1.75, 95% CI 1.13-2.72). For p16-negative disease, TNMv7 and TNMv8 demonstrated poor hazard discrimination. Different T, N stage and p16-status combinations did not improve prognostication after adjusting for other factors (CPE = 0.79 vs 0.79, p = 0.998). A model for p16-positive and p16-negative OPSCC including additional clinical characteristics improved 5-year OS prediction beyond TNMv8 (c-index 0.76 ± 0.02). Conclusions: TNMv8 is superior to TNMv7 for p16-positive OPSCC, but both performed poorly for p16-negative disease. A novel model incorporating additional clinical characteristics improved 5-year OS prediction for both p16-positive and p16-negative disease.
CitationPrice JM, West CM, Mistry HB, Betts G, Bishop P, Kennedy J, et al. Improved survival prediction for oropharyngeal cancer beyond TNMv8. Oral Oncol. 2021;115:105140.
- Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
- Authors: Freitag J, Wald T, Kuhnt T, Gradistanac T, Kolb M, Dietz A, Wiegand S, Wichmann G
- Issue date: 2020 Jan 1
- Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan.
- Authors: Mizumachi T, Homma A, Sakashita T, Kano S, Hatakeyama H, Fukuda S
- Issue date: 2017 Aug
- Prognostic Impact of AJCC/UICC 8th Edition New Staging Rules in Oropharyngeal Squamous Cell Carcinoma.
- Authors: Würdemann N, Wagner S, Sharma SJ, Prigge ES, Reuschenbach M, Gattenlöhner S, Klussmann JP, Wittekindt C
- Issue date: 2017
- Prognostic impact of combined immunoprofiles in oropharyngeal squamous cell carcinoma patients with respect to AJCC 8th edition.
- Authors: Gurin D, Slavik M, Hermanova M, Shatokhina T, Sana J, Kazda T, Selingerova I, Ahmad P, Smilek P, Horakova Z, Hendrych M, Slampa P, Slaby O
- Issue date: 2018 Oct
- Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 - Risk of incorrect downstaging of HPV-mediated non-tonsillar, non-base of tongue carcinomas.
- Authors: Marklund L, Holzhauser S, de Flon C, Zupancic M, Landin D, Kolev A, Haeggblom L, Munck-Wikland E, Hammarstedt-Nordenvall L, Dalianis T, Näsman A
- Issue date: 2020 Nov